Pharma Q2 Results Preview: Johnson & Johnson And Novartis
The earnings season is on us again with two heavyweights of health care hoping to show strong second-quarter results, while giving a glimpse into their prospects for the second half of the year. It will be Novartis' first chance to talk with investors about a new US Senate report regarding the company's dealings with Trump lawyer Cohen.
You may also be interested in...
CMS' Verma Touts Value-Based Payments After Cancellation Of Pilot For Novartis' Kymriah
'It's not for every medication,' CMS administrator says, but agency continues to explore how to apply value-based pricing.
Gilenya Patent Upheld, But Who's The Biggest Winner – Novartis or Celgene?
A composition of matter patent for the Novartis MS drug Gilenya expires in 2019, but a recent inter partes review decision upheld a dosing patent that doesn't expire until 2027. However, analysts also touted the victory as a big win for Celgene and its competing S1P modulator ozanimod.
Alarm As Novartis Exits Antibiotics Space
The Swiss major says that while the science for its antibacterial and antiviral research programs is compelling, "we have decided to prioritize our resources in other areas where we believe we are better positioned to develop innovative medicines."